MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:30Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Estrogens]]
			[[Category:Sex hormones]]
			[[Category:Hormone replacement therapy]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #56

2026-05-23T03:42:08Z

parser-claude batch MedTemplate pre-fill, Top 300 #56

New page

{{MedTemplate
| generic = Estradiol (17β-estradiol)
| brand = Estrace, Vivelle-Dot, Climara, Divigel, Evamist, Estring, Estraderm, Premarin (CEE, not strictly estradiol)
| structure =
| classes = [[:Category:Estrogens|Estrogen]], [[:Category:Sex_hormones|Sex hormone]], [[:Category:Hormone_replacement_therapy|Hormone replacement therapy]]
| uses = <vote slug="vasomotor-menopause-use">Vasomotor menopausal symptoms</vote>, <vote slug="genitourinary-menopause-use">Genitourinary syndrome of menopause</vote>, <vote slug="hypoestrogenism-use">Hypoestrogenism (e.g., POI, post-oophorectomy)</vote>, <vote slug="osteoporosis-prevention-use">Osteoporosis prevention</vote>, <vote slug="gender-affirming-hrt-use">Feminizing hormone therapy</vote>
| starting_dose = Oral 1-2 mg daily; transdermal patch 0.025-0.05 mg/d twice weekly; transdermal gel 0.5-1 g/d; vaginal 10 mcg tablet twice weekly for GSM. Always combine with a progestogen in patients with an intact uterus.
| preparations = Oral 0.5, 1, 2 mg tablets; transdermal patches (twice-weekly and once-weekly); 0.06% gel; 1.53 mg/spray topical; vaginal ring (Estring); vaginal tablet (Vagifem/Yuvafem); vaginal cream
| fda_max = Indication-specific; lowest effective dose for shortest duration is the WHI-era standard
| pill_id =
| routes = Oral, transdermal, vaginal, IM (estradiol valerate, cypionate)
| onset = Vasomotor relief 2-4 weeks; bone density gains over months
| duration = Route- and formulation-dependent
| halflife = ~13-20 hours (oral); transdermal pharmacokinetics buffer the peaks/troughs of oral dosing<ref name="estrace-label">FDA Prescribing Information, Estrace (estradiol), Allergan, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/004511s175lbl.pdf</ref>
| bioavailability = Oral ~5% (extensive first-pass to estrone and conjugates); transdermal bypasses first-pass, giving more physiologic estradiol:estrone ratio<ref name="estrace-label" />
| pregnancy = Contraindicated in pregnancy (use is not appropriate during gestation; class label X). Lactation considerations vary by indication.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="estradiol-mech-claim">Estradiol is the principal endogenous estrogen; it binds nuclear estrogen receptors ERα and ERβ to regulate transcription of genes governing reproductive tissue maintenance, bone turnover, lipid metabolism, vascular function, and central thermoregulation.</vote> Transdermal routes avoid hepatic first-pass and the resulting increase in clotting-factor synthesis, reducing VTE risk relative to oral therapy. The Women's Health Initiative established the now-standard "lowest effective dose for the shortest necessary duration" framing of menopausal HRT<ref name="estrace-label" />.
}}

== References ==
<references />

Estradiol - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #56